Nike's stock is trading higher following Lance Armstrong's decision to end his longstanding fight against the persistent U.S. Anti-Doping Agency (USADA), the nonprofit, congressionally recognized sports watchdog group that has long accused the iconic cyclist of juicing his Tour de France victories with performance-enhancing drugs. This stands in contrast to the stock retreating more that 5% on the eve of the initial announcement earlier in the summer that the USADA would reopen its case. While Nike and Oakley (a division of Luxottica LUX) have long been associated with Armstrong, we'd point out ...